All News
RheumNow Podcast- Methotrexate Mechanisms (2.28.20)
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
Why You Should Come to RheumNow Live March 13th
RheumNow Live kicks off its second annual meeting - a little, big meeting in Fort Worth - in just 2 weeks and I think you should be there.
Read Article
ACR Releases Reproductive Health Guidelines for Rheumatic Diseases
Today, the American College of Rheumatology (ACR) published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
Read Article
JAK Inhibitors Stimulate Osteoblasts
Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).
Read Article
Adverse Effects of Low-Dose Methotrexate from the CIRT Trial
Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are reported in the current issue of Annals of Internal Medicine.
BSR Guidelines for Giant Cell Arteritis
NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.
Read Article
Bimekizumab Effective in Active Psoriatic Arthritis
Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.
Read Article
DMARD Inertia by Registry Rheumatologists
A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).
Read Article
RheumNow Podcast- Best Biologics (2.7.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Start with Anti-TNF in RA? Not So Fast
The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.
Read Article
2019 EULAR Recommendations for the Management of Rheumatoid Arthritis
The 2019 update to the EULAR recommendations on the use of synthetic and biological disease-modifying antirheumatic drugs in rheumatoid arthritis (RA) have been published in Annals of Rheumatic Disease - highlighting the efforts of an international consensus committee effort.
In the end, the task force put forth 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs, glucocorticoids, biological DMARDs, biosimilar DMARDs, and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).
RheumNow Podcast- A Good First Impression (1.24.20)
Dr Jack Cush comments on this week's journal articles, reviews and studies.
Read Article
QD Clinic - "Doc, When Can I Stop?"
QD Clinic - Lessons from the clinic. In this video: Patients stable on a biologic need guidance on when, and if, they can stop their biologic.
Read Article
QD Clinic - Hepatitis B and Biologics
QD Clinic - Lessons from the clinic
Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?
Biosimilars for Rheum Disease: Failure to Launch
The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.
Read Article
Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis
A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.
Read Article
TULIP2 - Anifrolumab Succeeds in Lupus
NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.
Treatment of Statin-induced anti-HMGCR myopathy
Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of tr
Read Article
RheumNow Podcast- Knee Pain Knockout (1.10.20)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.
Read Article
Dr. John Cush RheumNow ( View Tweet)
